Chairman and CEO Gil Van Bokkelen, PhD, Discusses BARDA’s “Highly Relevant” Designation for MultiStem with GEN
Athersys researchers involved in making MultiStem®, an adult-derived "off-the-shelf" stem cell product. Athersys says it is working as fast as it can to launch a pivotal trial of its in acute respiratory distress syndrome (ARDS), after the clinical program received the “Highly Relevant” designation for COVID-19 from the Biomedical Advanced Research and Development Authority (BARDA). [Athersys]
Athersys says it is working as fast as it can to launch a pivotal trial of its MultiStem® adult-derived "off-the-shelf" stem cell product in acute respiratory distress syndrome (ARDS), after the clinical program received the “Highly Relevant” designation for COVID-19 from BARDA. [Athersys . . .
![Trials will evaluate vaccine's ability to elicit immune responses against a spectrum of HIV-1 strains.[4designersart-Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/May6_2011_22401855_GreenOrangeRedHIV_VirologyInstituteGetsHIVVaccineFunding3978120126-218x150.jpg "Multiple Sclerosis Drug Inhibits HIV Infection and Transmission in Human Immune Cells")
